Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Neoplasms

Explore clinical trials studying Fallopian Tube Neoplasms. Study availability and eligibility vary by location and protocol.

600 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Neoplasms trial results

Active, Not Recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

NCT01081262

Conditions
Adnexal Diseases, Borderline Ovarian Mucinous Tumor, Endocrine Gland Neoplasms, +38 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 248 locations
View Trial Details
Active, Not Recruiting

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Arizona Center for Cancer Care (ACCC) - Biltmore Scottsdale, Arizona, United States
  • University of Arizona Cancer Center - Research and Administration at Main Campus Tucson, Arizona, United States
  • Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center Burbank, California, United States
View all 177 locations
View Trial Details
Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 398 locations
View Trial Details
Active, Not Recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02489006

Conditions
Adnexal Diseases, Debulking Surgical Procedures, Endocrine Gland Neoplasms, +18 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Ottawa Regional Cancer Centre Ottawa, Ontario, Canada
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM Montreal, Quebec, Canada
View Trial Details
Active, Not Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947

Conditions
Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +58 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • AOA-HOPE Tucson, Arizona, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • HOAG Memorial Hospital Presbyterian Newport, California, United States
View all 14 locations
View Trial Details

Related conditions